A phase I dose-escalation study of buparlisib (BKM120), an oral pan-PI3K inhibitor, in Chinese patients with advanced solid tumors L. Zhang, B. Xu,K. Hazell,A. Gaur,J. Xu,L. Trandafir,Y. L. WuEUROPEAN JOURNAL OF CANCER(2013)引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要